Mark E Cooper1, Vlado Perkovic2, Janet B McGill3, Per-Henrik Groop4, Christoph Wanner5, Julio Rosenstock6, Uwe Hehnke7, Hans-Juergen Woerle7, Maximilian von Eynatten7. 1. Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia. Electronic address: mark.cooper@bakeridi.edu.au. 2. George Institute for Global Health, University of Sydney, New South Wales, Australia. 3. Washington University in St Louis, St Louis, MO. 4. Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland; Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland. 5. University of Würzburg, Würzburg, Germany. 6. Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX. 7. Boehringer Ingelheim, Ingelheim, Germany.
Abstract
BACKGROUND: Although assessment of cardiovascular safety is mandated by regulatory agencies for the development of new drugs to treat type 2 diabetes, evaluation of their renal safety has been relatively neglected. STUDY DESIGN: Individual patient-level data pooled analysis of 13 phase 2 or 3 randomized, double-blind, placebo-controlled, clinical trials of the dipeptidyl peptidase 4 inhibitor linagliptin. SETTING & PARTICIPANTS: Participants who participated in any of 13 randomized clinical trials and fulfilled predefined inclusion/exclusion criteria, such as being drug-naive (hemoglobin A1c, 7.0%-11.0% [53-97 mmol/mol]) or being on background glucose-lowering therapy (hemoglobin A1c, 6.5%-10.5% [48-91 mmol/mol]). INTERVENTION: Of 5,466 consenting individuals with inadequately controlled type 2 diabetes, 3,505 received linagliptin, 5mg/d, and 1,961 receivedplacebo. OUTCOMES: The primary kidney disease outcome was defined as first occurrence during the study of 6 predefined safety end points: new onset of moderate elevation of albuminuria (urinary albumin-creatinine ratio [ACR] >30 mg/g with baseline values ≤ 30 mg/g), new onset of severe elevation of albuminuria (ACR > 300 mg/g with baseline values ≤ 300 mg/g), reduction in kidney function (serum creatinine increase to ≥250 μmol/L from a baseline value <250 μmol/L), halving of estimated glomerular filtration rate (loss of baseline eGFR >50%), acute renal failure (ascertained from diagnostic codes), or death from any cause. MEASUREMENTS: Albuminuria was assessed using ACR. GFR was estimated using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. RESULTS: Cumulative exposure (person-years) was 1,751 for linagliptin and 1,055 for placebo. The primary composite outcome occurred in 448 (12.8%) and 306 (15.6%) participants in the linagliptin and placebo groups, respectively. Linagliptin treatment significantly reduced the hazard of kidney disease events by 16% compared with placebo (HR, 0.84; 95% CI, 0.72-0.97; P=0.02). LIMITATIONS: Retrospective and hypothesis-generating study involving short- to midterm clinical trials. CONCLUSIONS:Linagliptin was not associated with increased kidney disease risk in patients with type 2 diabetes. The potential of this drug to improve kidney disease outcomes warrants further investigation.
RCT Entities:
BACKGROUND: Although assessment of cardiovascular safety is mandated by regulatory agencies for the development of new drugs to treat type 2 diabetes, evaluation of their renal safety has been relatively neglected. STUDY DESIGN: Individual patient-level data pooled analysis of 13 phase 2 or 3 randomized, double-blind, placebo-controlled, clinical trials of the dipeptidyl peptidase 4 inhibitor linagliptin. SETTING & PARTICIPANTS: Participants who participated in any of 13 randomized clinical trials and fulfilled predefined inclusion/exclusion criteria, such as being drug-naive (hemoglobin A1c, 7.0%-11.0% [53-97 mmol/mol]) or being on background glucose-lowering therapy (hemoglobin A1c, 6.5%-10.5% [48-91 mmol/mol]). INTERVENTION: Of 5,466 consenting individuals with inadequately controlled type 2 diabetes, 3,505 received linagliptin, 5mg/d, and 1,961 received placebo. OUTCOMES: The primary kidney disease outcome was defined as first occurrence during the study of 6 predefined safety end points: new onset of moderate elevation of albuminuria (urinary albumin-creatinine ratio [ACR] >30 mg/g with baseline values ≤ 30 mg/g), new onset of severe elevation of albuminuria (ACR > 300 mg/g with baseline values ≤ 300 mg/g), reduction in kidney function (serum creatinine increase to ≥250 μmol/L from a baseline value <250 μmol/L), halving of estimated glomerular filtration rate (loss of baseline eGFR >50%), acute renal failure (ascertained from diagnostic codes), or death from any cause. MEASUREMENTS: Albuminuria was assessed using ACR. GFR was estimated using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. RESULTS: Cumulative exposure (person-years) was 1,751 for linagliptin and 1,055 for placebo. The primary composite outcome occurred in 448 (12.8%) and 306 (15.6%) participants in the linagliptin and placebo groups, respectively. Linagliptin treatment significantly reduced the hazard of kidney disease events by 16% compared with placebo (HR, 0.84; 95% CI, 0.72-0.97; P=0.02). LIMITATIONS: Retrospective and hypothesis-generating study involving short- to midterm clinical trials. CONCLUSIONS:Linagliptin was not associated with increased kidney disease risk in patients with type 2 diabetes. The potential of this drug to improve kidney disease outcomes warrants further investigation.
Authors: Kieren J Mather; Ionut Bebu; Chelsea Baker; Robert M Cohen; Jill P Crandall; Cyrus DeSouza; Jennifer B Green; M Sue Kirkman; Heidi Krause-Steinrauf; Mary Larkin; Jeremy Pettus; Elizabeth R Seaquist; Elsayed Z Soliman; Emily B Schroeder; Deborah J Wexler; Rodica Pop-Busui Journal: Diabetes Res Clin Pract Date: 2020-05-23 Impact factor: 5.602
Authors: David Cherney; Søren S Lund; Bruce A Perkins; Per-Henrik Groop; Mark E Cooper; Stefan Kaspers; Egon Pfarr; Hans J Woerle; Maximilian von Eynatten Journal: Diabetologia Date: 2016-06-17 Impact factor: 10.122
Authors: Jose Luis Górriz; Javier Nieto; Juan F Navarro-González; Pablo Molina; Alberto Martínez-Castelao; Luis M Pallardó Journal: J Clin Med Date: 2015-10-23 Impact factor: 4.241
Authors: Thomas Jax; Alin Stirban; Arne Terjung; Habib Esmaeili; Andreas Berk; Sandra Thiemann; Robert Chilton; Maximilian von Eynatten; Nikolaus Marx Journal: Cardiovasc Diabetol Date: 2017-01-21 Impact factor: 9.951